The Key Players In Getting Proleukin Approved
Your article "Heartbreak and triumph in biotech land" (Top of the News, Feb. 3) creates a false impression about the process leading to the recent Food & Drug Administration Advisory Committee recommendation for approval of Proleukin (Interleukin-2) as a treatment for kidney cancer. In particular, the article incorrectly implies that Chiron Corp.'s "savvy" management somehow played a key role in the approval process.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.